A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

Ronald L. Veselenak; Mark Shlapobersky; Richard B. Pyles; Qun Wei; Sean M. Sullivan; Nigel Bourne

doi:10.1016/j.vaccine.2012.09.057

A Vaxfectin^®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

Ronald L. Veselenak, Mark Shlapobersky, Richard B. Pyles, Qun Wei, Sean M. Sullivan, Nigel Bourne

Pediatrics

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin^®. Prophylactic immunization with Vaxfectin^®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin^®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

Original language	English (US)
Pages (from-to)	7046-7051
Number of pages	6
Journal	Vaccine
Volume	30
Issue number	49
DOIs	https://doi.org/10.1016/j.vaccine.2012.09.057
State	Published - Nov 19 2012

Keywords

DNA vaccine
Herpes simplex virus type 2
Therapeutic vaccine
Vaxfectin

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2012.09.057

Cite this

@article{c056c99da12d4b80a149f28c83631300,

title = "A Vaxfectin{\textregistered}-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes",

abstract = "Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin{\textregistered}. Prophylactic immunization with Vaxfectin{\textregistered}-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin{\textregistered}-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.",

keywords = "DNA vaccine, Herpes simplex virus type 2, Therapeutic vaccine, Vaxfectin",

author = "Veselenak, {Ronald L.} and Mark Shlapobersky and Pyles, {Richard B.} and Qun Wei and Sullivan, {Sean M.} and Nigel Bourne",

note = "Funding Information: Financial support: This work was supported by the National Institutes of Health National Institute of Allergy and Infectious Diseases [grant number 5R42AI065015 ].",

year = "2012",

month = nov,

day = "19",

doi = "10.1016/j.vaccine.2012.09.057",

language = "English (US)",

volume = "30",

pages = "7046--7051",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "49",

}

TY - JOUR

T1 - A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

AU - Veselenak, Ronald L.

AU - Shlapobersky, Mark

AU - Pyles, Richard B.

AU - Wei, Qun

AU - Sullivan, Sean M.

AU - Bourne, Nigel

N1 - Funding Information: Financial support: This work was supported by the National Institutes of Health National Institute of Allergy and Infectious Diseases [grant number 5R42AI065015 ].

PY - 2012/11/19

Y1 - 2012/11/19

N2 - Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin®. Prophylactic immunization with Vaxfectin®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

AB - Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin®. Prophylactic immunization with Vaxfectin®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

KW - DNA vaccine

KW - Herpes simplex virus type 2

KW - Therapeutic vaccine

KW - Vaxfectin

UR - http://www.scopus.com/inward/record.url?scp=84869078803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869078803&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.09.057

DO - 10.1016/j.vaccine.2012.09.057

M3 - Article

C2 - 23041125

AN - SCOPUS:84869078803

SN - 0264-410X

VL - 30

SP - 7046

EP - 7051

JO - Vaccine

JF - Vaccine

IS - 49

ER -